Experts are seeing a rise in the number of drug products being produced that contain highly potent compounds or active pharmaceutical ingredients with an estimate of 25% of drugs in development globally being highly potent. This market potential is also mirrored in the forecasts for the oncology sector. That market alone is expected to increase in value from $64bn in 2011 to an incredible $104bn by 2018. With around 60% of HPAPIs in development destined to treat cancer, it is unsurprising that many in the pharmaceutical industry are hailing HPAPIs as ‘the next big thing’.
Total Biopharma is therefore excited to announce our first annual HPAPI 2015 Industry Survey. From this survey we’ll be releasing a number of e-books and studies related to manufacturing high potency APIs to track its implementation and innovation across the globe. And we need YOU to contribute.
What’s in it for you?
You will automatically be entered into the prize draw to win 1 of 5 free passes to attend the World HPAPI Congress 2015 in Basel this November. Plus you will receive an exclusive copy of all materials generated from this survey.
The survey explores, amongst other things:
- The different industry perceptions as to what constitutes ‘high potency’
- Which organisations are actively involved in the manufacturing of high potency APIs
- The different industry levels of the hierarchy of control and occupational exposure limits
- Which areas of healthcare, therapeutic areas and patient populations, will be most highly impacted by the increase in production of high potency APIs
Please circulate this to those in your relevant network. Your contribution will go towards helping the important research in this exciting sector.
For more information please contact me directly at email@example.com.
Image from ThomasThomas